Engineered T lymphocytes secreting anti–CD19 T-cell engagers (STAb-T19) prevent the down-modulation of CD19 and result in rapid, efficient elimination of cancer cells by recruiting endogenous T cells, thus preventing CD19-positive… Click to show full abstract
Engineered T lymphocytes secreting anti–CD19 T-cell engagers (STAb-T19) prevent the down-modulation of CD19 and result in rapid, efficient elimination of cancer cells by recruiting endogenous T cells, thus preventing CD19-positive relapses associated with CD19-targeting CAR T-cell therapies.
               
Click one of the above tabs to view related content.